Targeting an allosteric binding site in the citrate transporter NaCT (SLC13A5)

Inside the cells of the human body, tiny machines work constantly to move essential nutrients across the protective barriers that surround them. One such machine is a protein called NaCT, which acts like a specialized gatekeeper for citrate, a molecule vital for energy production and the creation of fats. In a healthy person, this gate opens and closes with precision, allowing just the right amount of citrate to pass through. However, when this system malfunctions, the consequences can be severe. If the gate is broken and lets too much citrate build up, it can trigger a rare and devastating form of epilepsy in newborns. Conversely, if the gate is stuck shut or works too slowly, it can contribute to metabolic disorders like fatty liver disease. For decades, scientists trying to fix these problems have focused their efforts on the gate's main entrance, the spot where citrate naturally enters. They have designed drugs that look like citrate to jam this door, but this approach has limits. Because these drugs mimic the natural molecule, they are often difficult to control and can struggle to distinguish between the different types of gates found in the body.

A team of researchers has now discovered a completely different way to influence this gate. Instead of trying to block the main entrance, they found a hidden spot on the side of the machine, a small pocket located where two copies of the protein join together. By targeting this secondary location, they identified a new class of compounds that can turn the gate's activity down without ever touching the main door. This discovery, detailed in a recent study, suggests that scientists can now design medicines that are more precise and versatile, offering hope for treating both the rare epilepsy caused by broken gates and the common metabolic diseases caused by sluggish ones. While the current study focused on inhibitors, the researchers note that similar strategies could potentially be adapted in the future to restore function in broken gates.

The researchers began their search by looking at a detailed 3D map of the NaCT protein, created using advanced imaging techniques that freeze molecules in place. Using computer software, they scanned the surface of the protein to find any nooks or crannies that might be suitable for a drug to grab onto. While the main citrate entrance was well known, the software highlighted a previously overlooked pocket situated at the junction where two protein units meet. This pocket is lined with specific chemical features that make it attractive to certain types of molecules. The team reasoned that if a drug could bind to this side pocket, it might act like a wedge or a clamp, changing how the two protein units interact and, in turn, altering how the gate opens and closes.

To test this idea, the scientists used a powerful computer program to sift through millions of potential drug candidates. They filtered through a database of 3.5 million chemical structures, looking for molecules that would fit perfectly into this side pocket and form strong connections with the surrounding protein parts. From this massive digital search, they narrowed the list down to the most promising 30 candidates and purchased them for real-world testing. They placed these compounds into a laboratory setup where human cells were engineered to produce the NaCT gate. By measuring how much citrate the cells absorbed, they could see if the new compounds were successfully slowing down the gate. The results were immediate and clear: three of the compounds successfully reduced the amount of citrate entering the cells, proving that the side pocket was indeed a viable target.

Encouraged by these initial successes, the team moved to refine their findings. They took the most effective compound from the first round and ordered 26 slightly different versions of it, tweaking the chemical structure to see which changes made the drug stronger. This process, known as structure-activity relationship testing, revealed that certain chemical shapes worked much better than others. Specifically, they found that adding more oily, water-repelling parts to one side of the molecule and aromatic rings to the other significantly improved the drug's ability to bind to the pocket. This led to the identification of six new compounds that were much more potent than the original hits, with some able to block the gate at concentrations as low as 12.78 micromolar. Crucially, these new compounds did not harm the cells, suggesting they are safe enough to pursue further.

To ensure that these drugs were truly working on the specific side pocket they had identified, the researchers cross-referenced their findings with a massive collection of genetic data. They looked at a comprehensive map of every possible mutation in the NaCT gene, which showed how changes in the protein's structure affected its function. They found that a specific building block in the protein, called phenylalanine-362, played a critical role. In their computer models, this building block was positioned right where the new drugs were supposed to bind. The genetic data confirmed that when this specific building block was altered, the cells became much less sensitive to the drugs. This alignment between the computer predictions, the chemical tests, and the genetic evidence strongly suggests that the drugs are indeed latching onto the intended side pocket and not some other random spot on the protein.

The significance of this work lies in the new path it opens for drug development. For years, the only way to stop the NaCT gate was to compete directly with citrate at the main entrance, a strategy that is chemically restrictive and often leads to drugs that are too similar to the natural molecule. By proving that a side pocket exists and can be targeted, this study demonstrates that scientists can now design medicines that work in a fundamentally different way. These new compounds do not look like citrate; they are chemically distinct and bind to a location that controls the gate's mechanics from the outside. While the researchers note that more work is needed to confirm exactly how these drugs hold onto the protein and to ensure they work well in the complex environment of the human body, the discovery provides a solid foundation for future therapies. It offers a blueprint for creating medicines that could one day be tailored to shut down an overactive gate in metabolic disease, or potentially, in the future, prop open a broken one in genetic epilepsy, addressing two very different medical problems with a single, flexible strategy.